{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T12:28:56Z","timestamp":1768220936324,"version":"3.49.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Lung cancer can result in malignant pericardial effusion (MPE), impacting patient prognosis. Intrapericardial infusion of bevacizumab was an alternative treatment for MPE.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>We present the case of a 48-year-old female with stage IV lung adenocarcinoma and MPE. MPE was managed by intrapericardial infusion of bevacizumab. The first intrapericardial infusion of bevacizumab effectively controlled the MPE for 8\u00a0months. Cardiotoxicity quickly emerged after the second intrapericardial infusion of bevacizumab. After intensive treatment, the symptoms of cardiotoxicity resolved within 10\u00a0days.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The present case indicates that intrapericardial infusion of bevacizumab could lead to cardiotoxicity in MPE patient. Cardiac examinations should be conducted before and after anti-vascular endothelial growth factor treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1573297","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T05:31:24Z","timestamp":1760679084000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiotoxicity related to intrapericardial infusion of bevacizumab in the treatment of lung cancer-mediated malignant pericardial effusion: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Shilong","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenyang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huafeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","article-title":"Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis","volume":"53","author":"Abdel-Qadir","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.amjcard.2020.12.092","article-title":"Pericardial involvement in cancer","volume":"145","author":"Chahine","year":"2021","journal-title":"Am. J. Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.2147\/OTT.S90145","article-title":"Sustained response of malignant pericardial effusion to intrapericardial bevacizumab in an advanced lung cancer patient: a case report and literature review","volume":"8","author":"Chen","year":"2015","journal-title":"OncoTargets Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"52436","DOI":"10.18632\/oncotarget.9420","article-title":"Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"B5","doi-asserted-by":"publisher","first-page":"35262","DOI":"10.18632\/oncotarget.13064","article-title":"Greater efficacy of intracavitary infusion of bevacizumab compared to traditional local treatments for patients with malignant cavity serous effusion","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"B6","first-page":"483","article-title":"Prolonged survival in Colon cancer with malignant pericardial effusion and pulmonary lymphangitic carcinomatosis: a case for monoclonal antibodies?","volume":"80","author":"Del Rosario","year":"2016","journal-title":"Conn. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1245\/s10434-008-0059-z","article-title":"Severe pericardial effusion in patients with concurrent malignancy: a retrospective analysis of prognostic factors influencing survival","volume":"15","author":"Dequanter","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1634\/theoncologist.2009-0155","article-title":"Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials","volume":"15","author":"Geiger-Gritsch","year":"2010","journal-title":"Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"5211","DOI":"10.1200\/JCO.2005.00.745","article-title":"Abnormal cytology predicts poor prognosis in cancer patients with pericardial effusion","volume":"23","author":"Gornik","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"6763625","DOI":"10.1155\/2022\/6763625","article-title":"Efficacy of intrapleural or intrapericardial injection of single bevacizumab in the treatment of lung cancer-mediated malignant effusion","volume":"2022","author":"He","year":"2022","journal-title":"Can. Respir. J."},{"key":"B11","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"ESC guidelines on cardio-oncology developed in collaboration with the european hematology association (EHA), the european society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3390\/life13020366","article-title":"Cardiovascular toxicity induced by vascular endothelial growth factor inhibitors","volume":"13","author":"Mihalcea","year":"2023","journal-title":"Life (Basel, Switzerland)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/1759-7714.13238","article-title":"A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non-small-cell lung cancer","volume":"11","author":"Nie","year":"2020","journal-title":"Thorac. Cancer"},{"key":"B14","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ctrv.2010.11.001","article-title":"Cardiovascular effects of systemic cancer treatment","volume":"37","author":"Senkus","year":"2011","journal-title":"Cancer Treat. Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1001\/archsurg.1997.01430290087018","article-title":"Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer","volume":"132","author":"Takahashi","year":"1997","journal-title":"Archives Surg."},{"key":"B17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.gore.2016.01.006","article-title":"Bevacizumab helped resolve pericardial and pleural effusion that was associated with malignant ovarian clear cell carcinoma","volume":"16","author":"Ueda","year":"2016","journal-title":"Gynecol. Oncol. Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s00059-019-4833-4","article-title":"Management of neoplastic pericardial disease","volume":"45","author":"Zhang","year":"2020","journal-title":"Herz"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1573297\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T05:31:24Z","timestamp":1760679084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1573297\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":18,"alternative-id":["10.3389\/fphar.2025.1573297"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1573297","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"article-number":"1573297"}}